MAPT and Alzheimer disease: , a neuroprotective role for Ldlr was described as Ldlr overexpression attenuated tau pathology through preservation of myelin, inhibiting microglial activation, and reducing ApoE levels, suggesting drug discovery directed towards increasing Ldlr levels as a treatment option for AD and other tauopathies57.